Argent Biopharma Limited has released a press release.
Epilepsy Clinical Study Comparing CannEpil to 100% CBD
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- Placement Settlement Complete, Info on the Priority Offer
- Appendix 4E and Audited 2019 Financial Report
- Approval Granted for Large-Scale Research Project with IHPS
- Trial on the Effect of CannEpil on Driver Competency
- Canaccord to Lead LSE Listing and $4.75m Placement Closed
Later from Argent Biopharma
- 200 Prescription Milestone Passed in Australia & UK
- MGC Pharma Passes 400 Prescription Milestone in September
- 600 Prescription Milestone Passed for MGC Pharma Products
- 800 Prescription Milestone Passed for MGC Pharma Products
- MGC Reaches 1,000 Prescription Milestone Ahead of Schedule
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma